Immunology of simultaneous liver and kidney transplants with identification and prevention of rejection
Open Access
- 1 November 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 1
Abstract
Simultaneous liver and kidney (SLK) transplantation is considered the best treatment modality among selected patients with both chronic kidney disease (CKD) and end-stage liver disease (ESLD). Since the first SLK transplant in 1983, the number of SLK transplants has increased worldwide, and particularly in the United States since the implementation of the MELD system in 2002. SLK transplants are considered a relatively low immunological risk procedure evidenced by multiple studies displaying the immunomodulatory properties of the liver on the immune system of SLK recipients. SLK recipients demonstrate lower rates of both cellular and antibody-mediated rejection on the kidney allograft when compared to kidney transplant-alone recipients. Therefore, SLK transplants in the setting of preformed donor-specific HLA antibodies (DSA) are a common practice, at many centers. Acceptance and transplantation of SLKs are based solely on ABO compatibility without much consideration of crossmatch results or DSA levels. However, some studies suggest an increased risk for rejection for SLK recipients transplanted across high levels of pre-formed HLA DSA. Despite this, there is no consensus regarding acceptable levels of pre-formed DSA, the role of pre-transplant desensitization, splenectomy, or immunosuppressive management in this unique population. Also, the impact of post-transplant DSA monitoring on long-term outcomes is not well-studied in SLK recipients. In this article, we review recent and relevant past articles in this field with a focus on the immunological risk factors among SLK recipients, and strategies to mitigate the negative outcomes among them.Keywords
This publication has 77 references indexed in Scilit:
- Combined Liver-Kidney Transplants: Allosensitization and Recipient OutcomesTransplantation, 2011
- Postischemic Inflammatory Response in an Auxiliary Liver Graft Predicts Renal Graft Outcome in Sensitized PatientsTransplantation, 2011
- Donor-Directed MHC Class I Antibody Is Preferentially Cleared from Sensitized Recipients of Combined Liver/Kidney TransplantsAmerican Journal of Transplantation, 2011
- The Significance of Donor-Specific HLA Antibodies in Rejection and Ductopenia Development in ABO Compatible Liver TransplantationAmerican Journal of Transplantation, 2011
- Acute allograft rejection in human liver transplant recipients is associated with signaling through toll‐like receptor 4Journal of Gastroenterology and Hepatology, 2010
- Successful Combined Partial Auxiliary Liver and Kidney Transplantation in Highly Sensitized Cross-Match Positive RecipientsAmerican Journal of Transplantation, 2007
- HLAMatchmaker: A Molecularly Based Algorithm for Histocompatibility Determination. V. Eplet Matching for HLA-DR, HLA-DQ, and HLA-DPHuman Immunology, 2007
- THE LIVER NEITHER PROTECTS THE KIDNEY FROM REJECTION NOR IMPROVES KIDNEY GRAFT SURVIVAL AFTER COMBINED LIVER AND KIDNEY TRANSPLANTATION FROM THE SAME DONOR1Transplantation, 1996
- SPECIFIC ABSORPTION OF LYMPHOCYTOTOXIC ALLOANTIBODIES BY THE LIVER IN INBRED RATSTransplantation, 1990
- COMBINED LIVER AND KIDNEY TRANSPLANTATIONThe Lancet, 1984